(5-isopropyl-thiazol-2-yl)-pyridin-2-yl-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-isopropyl-thiazol-2-yl)-pyridin-2-yl-amine
• 英文别名: 5-propan-2-yl-N-pyridin-2-yl-1,3-thiazol-2-amine
• 化学式: C₁₁H₁₃N₃S
• 分子量: 219.31
• InChiKey: FYHWFVUBUSBQLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Thiazole derivatives
  申请人：Pfizer Inc.

  公开号：US20030078252A1

  公开（公告）日：2003-04-24

  The invention provides compounds of formula 1 1 wherein R 1 , R 3 , and R 4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

  该发明提供了具有11式的化合物，其中R1、R3和R4如所定义，并其药学上可接受的盐。据指出，11式化合物具有抑制cdk5、cdk2和GSK-3活性的作用。描述了包括11式化合物的药物组合物和方法，用于治疗包括异常细胞增长在内的疾病和病况，如癌症、神经退行性疾病以及受多巴胺神经传导影响的疾病和病况。还描述了包括11式化合物的药物组合物和方法，用于治疗男性生育能力和精子活动性；糖尿病；糖耐量受损；代谢综合征或X综合征；多囊卵巢综合征；脂肪生成和肥胖；肌肉生成和脆弱性，例如与年龄相关的身体表现下降；急性肌肉萎缩，例如与烧伤、卧床、肢体固定或主要胸部、腹部和/或骨科手术相关的肌肉萎缩和/或虚弱；败血症；脱发、头发变薄和秃头；以及免疫缺陷。
• Macromolecules having hydrazide attachment moieties and reagents for their production
  申请人：——

  公开号：US20040087807A1

  公开（公告）日：2004-05-06

  This invention relates to attachment chemistries for binding macromolecules to a substrate surface or to other conjugation targets. More particularly, this invention relates to attachment chemistries involving branched or linear structures having one or more hydrazide attachment moieties for binding the macromolecules to a substrate surface, or for other conjugation reactions. Novel modifying reagents are provided for the introduction of protected hydrazide attachment moieties or precursor forms of such hydrazides to the macromolecule, either as a single hydrazide or as multiple hydrazides.

  这项发明涉及用于将大分子结合到基底表面或其他共轭靶标的附着化学物质。更具体地说，这项发明涉及涉及分支或线性结构的附着化学物质，具有一个或多个肼酰肼附着基团，用于将大分子结合到基底表面，或用于其他共轭反应。提供了用于引入受保护的肼酰肼附着基团或此类肼酰肼的前体形式到大分子中的新型修饰试剂，可以作为单个肼酰肼或多个肼酰肼。
• Thiazole derivatives and their use as cdk inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1256578A1

  公开（公告）日：2002-11-13

  The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

  本发明提供了式 1 的化合物 其中 R1、R3 和 R4 如所定义，以及它们的药学上可接受的盐类。式 1 的化合物具有抑制 cdk5、cdk2 和 GSK-3 的活性。描述了包含式 1 化合物的药物组合物和方法，用于治疗包含异常细胞生长的疾病和病症，如癌症、神经退行性疾病和病症以及受多巴胺神经传递影响的疾病和病症。还描述了包含式 1 化合物的药物组合物和方法，用于治疗男性生育力和精子活力、糖尿病、糖耐量受损、代谢综合征或 X 综合征、多囊卵巢综合征、脂肪生成和肥胖症；肌肉生成和虚弱，例如与年龄有关的体能下降；急性肌肉疏松症，例如与烧伤、卧床休息、肢体固定或胸部、腹部和/或骨科大手术有关的肌肉萎缩和/或恶病质；败血症；脱发、头发稀疏和秃顶；以及免疫缺陷。
• US6720427B2
  申请人：——

  公开号：US6720427B2

  公开（公告）日：2004-04-13